中国临床药理学杂志2017，Vol.33Issue(15)：1484-1487,4.DOI:10.13699/j.cnki.1001-6821.2017.15.032
马来酸桂哌齐特用药患者11665例的血液系统药品不良反应自动监测研究
Automatic monitoring research on hematological adrs induced by cinepazide maleate in 11665 patients
摘要
Abstract
Objective To provide reliable drugs security information for clinic,we acquired incidences of hematological adverse drug reactions (ADRs) induced by cinepazide maleate among a large population by automatic monitoring system.Methods Automatic monitoring was implemented on all inpatients who received cinepazide in hospital information system retrospectively,including two specifications of 80 mg/2 mL and 320 mg/10 mL,from August 1st,2014 to June 31th,2016.Then suspected cases submitted by system were manually reviewed.Results A total of 11665 patients were monitored.The incidences of thrombocytopenia,anemia and leucopenia were 0.12％,0.34％ and 0.2％ respectively,and the incidence of hematological ADRs was 0.66％ (no patients with two or more ADRs).17 patients had granulocytopenia,but they were under the diagnostic standard of agranulocytosis.Thrombocytopenia and anemia usually occurred after 5 days,while leucopenia occurred after nearly 10 days.Infection was one of risk factors causing hematological ADRs.Conclusion The incidences of hematological ADRs induced by cinepazide were from 0.1％ to 1％.When prescribing cinepazide for infective old patients with combined medications,doctors should reduce the routine dose and pay more attention to patients to detect ADR and avoid bad outcomes timely.Data in hospital information system were analyzed through automatic monitoring system,which is helpful to implement safety monitoring on more drugs in a large population and acquire accurate incidences of ADRs efficiently.关键词
桂哌齐特注射液/药品不良反应/自动监测/白细胞减少/血小板减少/血红蛋白减少Key words
cinepazide injection/adverse drug reaction/automatic monitoring/leucopenia/anemia/thrombocytopenia分类
医药卫生引用本文复制引用
郭代红,胡鹏洲,王啸宇,刘佳,夏玉坤,马亮,范琦,田小燕..马来酸桂哌齐特用药患者11665例的血液系统药品不良反应自动监测研究[J].中国临床药理学杂志,2017,33(15):1484-1487,4.基金项目
全军后勤科研重点基金资助项目(BWS14R039) （BWS14R039）
国家药品评价中心委托专项(马来酸桂哌齐特注射液的安全性研究)基金资助项目 （马来酸桂哌齐特注射液的安全性研究）
